Literature DB >> 27074083

Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.

Anne Chastre1, David A Hafler1, Kevin C O'Connor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27074083      PMCID： PMC4918464          DOI： 10.1056/NEJMc1513302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.

Authors:  Elodie Nerrant; Céline Salsac; Mahmoud Charif; Xavier Ayrignac; Clarisse Carra-Dalliere; Giovanni Castelnovo; Radjiv Goulabchand; Julie Tisseyre; Cédric Raoul; Jean-François Eliaou; Pierre Labauge; Thierry Vincent
Journal:  Mult Scler       Date:  2014-04-22       Impact factor: 6.312

2.  Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?

Authors:  Bernhard Hemmer
Journal:  Mult Scler       Date:  2015-01-12       Impact factor: 6.312

3.  Multiple Sclerosis and Antibodies against KIR4.1.

Authors:  Anne-Katrin Pröbstel; Jens Kuhle; Anne-Catherine Lecourt; Isabelle Vock; Nicholas S R Sanderson; Ludwig Kappos; Tobias Derfuss
Journal:  N Engl J Med       Date:  2016-04-14       Impact factor: 91.245

4.  Potassium channel KIR4.1 as an immune target in multiple sclerosis.

Authors:  Rajneesh Srivastava; Muhammad Aslam; Sudhakar Reddy Kalluri; Lucas Schirmer; Dorothea Buck; Björn Tackenberg; Veit Rothhammer; Andrew Chan; Ralf Gold; Achim Berthele; Jeffrey L Bennett; Thomas Korn; Bernhard Hemmer
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

5.  Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.

Authors:  Adipong Brickshawana; Shannon R Hinson; Michael F Romero; Claudia F Lucchinetti; Yong Guo; Mathias Buttmann; Andrew McKeon; Sean J Pittock; Min-Hwang Chang; An-Ping Chen; Thomas J Kryzer; James P Fryer; Sarah M Jenkins; Philippe Cabre; Vanda A Lennon
Journal:  Lancet Neurol       Date:  2014-07-06       Impact factor: 44.182

6.  Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.

Authors:  Kishore Malyavantham; Bianca Weinstock-Guttman; Lakshmanan Suresh; Robert Zivadinov; Thomas Shanahan; Darlene Badgett; Murali Ramanathan
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240
  6 in total
  8 in total

Review 1.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

Review 2.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 3.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

Review 4.  An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.

Authors:  Marwa Kaisey; Ghazal Lashgari; Justyna Fert-Bober; Daniel Ontaneda; Andrew J Solomon; Nancy L Sicotte
Journal:  Curr Neurol Neurosci Rep       Date:  2022-10-21       Impact factor: 6.030

Review 5.  KIR4.1: K+ Channel Illusion or Reality in the Autoimmune Pathogenesis of Multiple Sclerosis.

Authors:  Chen Gu
Journal:  Front Mol Neurosci       Date:  2016-09-27       Impact factor: 5.639

6.  Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.

Authors:  Miquel Navas-Madroñal; Ana Valero-Mut; María José Martínez-Zapata; Manuel Javier Simón-Talero; Sebastián Figueroa; Nuria Vidal-Fernández; Mariana López-Góngora; Antonio Escartín; Luis Querol
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

Review 7.  Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.

Authors:  Michie Imamura; Osamu Higuchi; Yasuhiro Maeda; Akihiro Mukaino; Mitsuharu Ueda; Hidenori Matsuo; Shunya Nakane
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

Review 8.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.